Global Ganja Report

The news that CBD products will be arriving at Walgreens and CVS drugstore chains can be seen as further progress for the normalization of cannabis. But it is also a further indication of corporate control of the new cannabis economy.

The conventional wisdom—and certainly the impression made by much media and advertising—is that CBD is legal pursuant to the federal Farm Bill enacted late last year. As is often the case, however, there are some devils in the details.

FDA commissioner Scott Gottlieb has suddenly announced that he is stepping down, leaving lots of unfinished business—including the status of CBD under the agency's regs. Biotech stocks are taking a tumble on the news, while tobacco is bullish and cannabis is mixed.

A newly released study from the University of New Mexico actually finds more therapeutic benefits to THC than its sexy sibling cannabinoid CBD. However, the study is based on a single cellphone app—which, for better or worse, is certainly unorthodox methodology.

Following the crackdown on CBD-infused foods and beverages by authorities in New York City and elsewhere, Capitol Hill lawmakers are formally calling upon the FDA to provide immediate clarity on the question. Meanwhile, New York, at least is starting to lift the pressure.

Latin America is at the forefront of the global wave of cannabis law reform, according to a new report from a DC-based industry analyst. New Frontier Data sees a $9.8 billion market in the region, with big expansion potential for both exports and serving local consumption. 

A bill that would legalize "recreational" cannabis is moving forward in Hawaii's state legislature. It would build on the dispensary system established by the state's medical marijuana program to bring about a regulated adult-use market.

CBD-infused foods and beverages are the target of a crackdown in New York City, as well as Maine and Ohio. A budding business of cannabinoid-enhanced concoctions and libations is feeling a sudden pinch. But some media coverage is failing to make clear that what is at issue here is the FDA's failure to keep pace with federal law—not any inherent risks of cannabidiol.